More recently, vaccination with WT1 peptide-loaded dendritic cells (DCs), coupled with targeted immunotherapy and/or traditional chemotherapy, was investigated in five RCC and five bladder cancer patients with relapsed or refractory disease. This evidence concerns the gene WT1 and renal cell carcinoma.